COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response

Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its rela...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 61; p. 127420
Main Authors Tong, Sherry, Litwin, Sean M., Epel, Elissa S., Lin, Jue, Drury, Stacy S., Hecht, Frederick M., Robinson, James E., Prather, Aric A., Norton, Elizabeth B.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 13.08.2025
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0264-410X
1873-2518
1873-2518
DOI10.1016/j.vaccine.2025.127420

Cover

Abstract Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.
AbstractList AbstractSevere SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.
Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.
Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.
Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.
ArticleNumber 127420
Author Tong, Sherry
Robinson, James E.
Litwin, Sean M.
Drury, Stacy S.
Prather, Aric A.
Hecht, Frederick M.
Lin, Jue
Norton, Elizabeth B.
Epel, Elissa S.
Author_xml – sequence: 1
  givenname: Sherry
  surname: Tong
  fullname: Tong, Sherry
  organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America
– sequence: 2
  givenname: Sean M.
  surname: Litwin
  fullname: Litwin, Sean M.
  organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America
– sequence: 3
  givenname: Elissa S.
  surname: Epel
  fullname: Epel, Elissa S.
  organization: Center for Health and Community, University of California, San Francisco, CA, United States of America
– sequence: 4
  givenname: Jue
  surname: Lin
  fullname: Lin, Jue
  organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA, United States of America
– sequence: 5
  givenname: Stacy S.
  surname: Drury
  fullname: Drury, Stacy S.
  organization: Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States of America
– sequence: 6
  givenname: Frederick M.
  surname: Hecht
  fullname: Hecht, Frederick M.
  organization: Department of Medicine, University of California, San Francisco, CA, United States of America
– sequence: 7
  givenname: James E.
  surname: Robinson
  fullname: Robinson, James E.
  organization: Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States of America
– sequence: 8
  givenname: Aric A.
  surname: Prather
  fullname: Prather, Aric A.
  organization: Center for Health and Community, University of California, San Francisco, CA, United States of America
– sequence: 9
  givenname: Elizabeth B.
  surname: Norton
  fullname: Norton, Elizabeth B.
  email: enorton@tulane.edu
  organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40561567$$D View this record in MEDLINE/PubMed
BookMark eNqNks9uEzEQxi1URNPCI4AsceGywfba3vUBUBT-Vaqo1JSKm-X1joXDxhvsbETehmfhyfBqQw-VEBwsy5rffDP-Zs7QSegDIPSUkjklVL5cz_fGWh9gzggTc8oqzsgDNKN1VRZM0PoEzQiTvOCUfDlFZymtCSGipOoROuVESCpkNUPt8ur24m1BFd5cf1rgPuK9j6bDe7C78THVwLvDFrAJLU5Ds84hnOAH9sF1AwSbw18BrxbXq2LZ3xbs18-bwkLX4Qhp24cEj9FDZ7oET473Ofr8_t3N8mNxefXhYrm4LCxXaldII0vgrjUA-TQUXFMLCspRrmyjpGDSKcVpVVkliKwrJQBK58rSSSlMXZ6jF5PuNvbfB0g7vfFp7MQE6IekS8Y4E7ziIqPP76Hrfoghd5cpzspKUEIy9exIDc0GWr2NfmPiQf_xLwNiAmzsU4rg7hBK9DgnvdZHD_U4Jz3NKee9mfIg27H3EHWyfrSy9THbq9ve_1Ph9T0F2_ngrem-wQHS3W-oTkwTvRp3YVwFJgipaDUKvPq7wH808BvPK8TO
Cites_doi 10.1126/sciimmunol.abl5344
10.1038/s41586-022-04460-3
10.1056/NEJMoa2034577
10.1016/j.cell.2022.01.015
10.1038/s41541-024-00895-z
10.1101/gr.1239303
10.1038/s41591-021-01377-8
10.1038/s41586-020-03041-6
10.1126/science.abm0829
10.15585/mmwr.mm7315a2
10.1126/science.add2897
10.1038/s41586-020-2700-3
10.1038/s41586-021-03841-4
10.1016/j.cell.2020.08.017
10.1016/j.cell.2022.05.022
10.1038/s41541-023-00731-w
10.1016/j.immuni.2021.08.001
10.1038/ni.3031
10.1038/s41590-021-01084-z
10.1093/cid/ciac397
10.7554/eLife.72619
10.1016/j.vaccine.2009.10.091
10.1038/s41577-020-0348-8
10.1056/NEJMc2108829
10.1016/j.cell.2020.09.038
10.1056/NEJMoa2114228
10.1111/j.1365-2567.2008.02813.x
10.1126/science.abc8511
10.1126/science.abj9853
10.1126/science.abj4176
10.1056/NEJMc2202061
10.1038/s41590-020-0782-6
10.1038/s41591-021-01386-7
10.1038/s41598-023-33320-x
10.1038/s41586-022-04465-y
10.1038/s43587-022-00343-4
10.1038/nri2394
10.1126/science.abm3425
10.1056/NEJMoa2114583
10.1038/s41586-021-04387-1
ContentType Journal Article
Copyright 2025 The Authors
The Authors
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Copyright © 2025. Published by Elsevier Ltd.
Copyright_xml – notice: 2025 The Authors
– notice: The Authors
– notice: Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
– notice: Copyright © 2025. Published by Elsevier Ltd.
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
C1K
H94
K9.
M7N
NAPCQ
7X8
DOI 10.1016/j.vaccine.2025.127420
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Virology and AIDS Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Safety Science Abstracts
Immunology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
Nursing & Allied Health Premium

MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 127420
ExternalDocumentID 40561567
10_1016_j_vaccine_2025_127420
S0264410X25007170
1_s2_0_S0264410X25007170
Genre Journal Article
GeographicLocations United States--US
San Francisco California
California
GeographicLocations_xml – name: San Francisco California
– name: United States--US
– name: California
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: U54 CA260581
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
5RE
5VS
7-5
71M
7RV
8C1
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AEXOQ
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGGSO
AGUBO
AGYEJ
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BBNVY
BENPR
BHPHI
BKOJK
BLXMC
BNPGV
CJTIS
CNWQP
CS3
EBS
EFJIC
EFKBS
EFLBG
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HCIFZ
IHE
J1W
KOM
L7B
LUGTX
LW9
M29
M2O
M41
M7P
MO0
N9A
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
Q38
ROL
RPZ
SAB
SCC
SDF
SDG
SDP
SES
SEW
SNL
SPCBC
SSH
SSI
SSZ
T5K
UV1
WH7
Z5R
~G-
~HD
.GJ
29Q
53G
7X7
88E
8AO
8FE
8FH
8FI
8FJ
8G5
AAQXK
ABUWG
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
ADVLN
AEUYN
AFKRA
AGHFR
AGQPQ
AHHHB
AQUVI
ASPBG
AVWKF
AZFZN
AZQEC
BKEYQ
BKNYI
BPHCQ
BVXVI
CCPQU
DWQXO
EJD
FEDTE
FGOYB
FYUFA
G-2
GNUQQ
GUQSH
HEJ
HLV
HMCUK
HMG
HMK
HMO
HVGLF
HX~
HZ~
K9-
LK8
M0R
M0T
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
R2-
SAE
SIN
SVS
UKHRP
WOW
WUQ
XPP
ZGI
ZXP
6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
ACMHX
ADSLC
AGWPP
C1K
H94
K9.
M7N
7X8
ID FETCH-LOGICAL-c499t-6a63e4fdaeedaeb1efb851e9f149cb96526f994177c95068795ee3ff33f665a83
IEDL.DBID .~1
ISSN 0264-410X
1873-2518
IngestDate Fri Sep 05 15:48:26 EDT 2025
Sun Aug 24 03:44:10 EDT 2025
Tue Sep 09 02:32:30 EDT 2025
Wed Aug 27 16:28:06 EDT 2025
Sat Sep 20 17:13:03 EDT 2025
Sat Sep 20 19:12:18 EDT 2025
Sat Sep 20 06:20:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19 vaccine
Sex differences
SARS-CoV-2
T-cell
Language English
License This is an open access article under the CC BY license.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c499t-6a63e4fdaeedaeb1efb851e9f149cb96526f994177c95068795ee3ff33f665a83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0264410X25007170
PMID 40561567
PQID 3242375100
PQPubID 105530
PageCount 1
ParticipantIDs proquest_miscellaneous_3224254745
proquest_journals_3242375100
pubmed_primary_40561567
crossref_primary_10_1016_j_vaccine_2025_127420
elsevier_sciencedirect_doi_10_1016_j_vaccine_2025_127420
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X25007170
elsevier_clinicalkey_doi_10_1016_j_vaccine_2025_127420
PublicationCentury 2000
PublicationDate 2025-08-13
PublicationDateYYYYMMDD 2025-08-13
PublicationDate_xml – month: 08
  year: 2025
  text: 2025-08-13
  day: 13
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: Kidlington
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2025
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Hutnick (bb0170) 2010; 28
Bowyer (bb0210) 2018; 6
Tarke (bb0105) 2022; 185
Cohen (bb0040) 2021; 2
Neidleman (bb0155) 2021; 10
Tarke (bb0165) 2021; 2
Levin (bb0140) 2021; 385
Polack (bb0020) 2020; 383
Sekine (bb0060) 2020; 183
Zhang (bb0130) 2022; 185
Guerrera (bb0095) 2021; 6
Liu (bb0125) 2022; 603
Painter (bb0150) 2021; 54
Zambrano (bb0200) 2024; 73
Rakshit (bb0135) 2023; 8
Gilbert (bb0005) 2022; 375
Rydyznski Moderbacher (bb0055) 2020; 183
Chang, Wherry, Goldrath (bb0035) 2014; 15
Goldberg (bb0015) 2021; 385
Gray (bb0080) 2022; 386
Shapiro (bb0205) 2022; 75
Barouch (bb0120) 2021; 385
Pegu (bb0145) 2021; 373
(bb0220) 2020
McMahan (bb0090) 2021; 590
(bb0225) 2022
(bb0230) 2022
Mateus (bb0100) 2021; 374
Shannon (bb0235) 2003; 13
Peng (bb0045) 2022; 23
Prather (bb0025) 2023; 13
Cele (bb0075) 2022; 602
Peng (bb0050) 2020; 21
Bange (bb0070) 2021; 27
Scully, Haverfield, Ursin, Tannenbaum, Klein (bb0175) 2020; 20
Wherry, Barouch (bb0085) 2022; 377
Gardner (bb0190) 2024; 9
Oberhardt (bb0115) 2021; 597
Thieme (bb0065) 2020; 1
Keeton (bb0030) 2022; 603
Mathew (bb0160) 2020; 369
Goel (bb0110) 2021; 374
Takahashi (bb0185) 2020; 588
Khoury (bb0010) 2021; 27
Jo (bb0215) 2023; 3
Fish (bb0180) 2008; 8
Sojka, Huang, Fowell (bb0195) 2008; 124
Gilbert (10.1016/j.vaccine.2025.127420_bb0005) 2022; 375
Mateus (10.1016/j.vaccine.2025.127420_bb0100) 2021; 374
Barouch (10.1016/j.vaccine.2025.127420_bb0120) 2021; 385
Gray (10.1016/j.vaccine.2025.127420_bb0080) 2022; 386
Gardner (10.1016/j.vaccine.2025.127420_bb0190) 2024; 9
Peng (10.1016/j.vaccine.2025.127420_bb0050) 2020; 21
Mathew (10.1016/j.vaccine.2025.127420_bb0160) 2020; 369
Keeton (10.1016/j.vaccine.2025.127420_bb0030) 2022; 603
Goldberg (10.1016/j.vaccine.2025.127420_bb0015) 2021; 385
Thieme (10.1016/j.vaccine.2025.127420_bb0065) 2020; 1
Shannon (10.1016/j.vaccine.2025.127420_bb0235) 2003; 13
McMahan (10.1016/j.vaccine.2025.127420_bb0090) 2021; 590
Painter (10.1016/j.vaccine.2025.127420_bb0150) 2021; 54
Wherry (10.1016/j.vaccine.2025.127420_bb0085) 2022; 377
Goel (10.1016/j.vaccine.2025.127420_bb0110) 2021; 374
Bange (10.1016/j.vaccine.2025.127420_bb0070) 2021; 27
Cohen (10.1016/j.vaccine.2025.127420_bb0040) 2021; 2
Zambrano (10.1016/j.vaccine.2025.127420_bb0200) 2024; 73
Hutnick (10.1016/j.vaccine.2025.127420_bb0170) 2010; 28
Takahashi (10.1016/j.vaccine.2025.127420_bb0185) 2020; 588
Levin (10.1016/j.vaccine.2025.127420_bb0140) 2021; 385
Polack (10.1016/j.vaccine.2025.127420_bb0020) 2020; 383
Tarke (10.1016/j.vaccine.2025.127420_bb0165) 2021; 2
Jo (10.1016/j.vaccine.2025.127420_bb0215) 2023; 3
Rydyznski Moderbacher (10.1016/j.vaccine.2025.127420_bb0055) 2020; 183
Shapiro (10.1016/j.vaccine.2025.127420_bb0205) 2022; 75
Oberhardt (10.1016/j.vaccine.2025.127420_bb0115) 2021; 597
Zhang (10.1016/j.vaccine.2025.127420_bb0130) 2022; 185
(10.1016/j.vaccine.2025.127420_bb0225) 2022
Tarke (10.1016/j.vaccine.2025.127420_bb0105) 2022; 185
Scully (10.1016/j.vaccine.2025.127420_bb0175) 2020; 20
Fish (10.1016/j.vaccine.2025.127420_bb0180) 2008; 8
Bowyer (10.1016/j.vaccine.2025.127420_bb0210) 2018; 6
Guerrera (10.1016/j.vaccine.2025.127420_bb0095) 2021; 6
Rakshit (10.1016/j.vaccine.2025.127420_bb0135) 2023; 8
(10.1016/j.vaccine.2025.127420_bb0230) 2022
Khoury (10.1016/j.vaccine.2025.127420_bb0010) 2021; 27
Pegu (10.1016/j.vaccine.2025.127420_bb0145) 2021; 373
Neidleman (10.1016/j.vaccine.2025.127420_bb0155) 2021; 10
Sojka (10.1016/j.vaccine.2025.127420_bb0195) 2008; 124
Liu (10.1016/j.vaccine.2025.127420_bb0125) 2022; 603
Chang (10.1016/j.vaccine.2025.127420_bb0035) 2014; 15
Prather (10.1016/j.vaccine.2025.127420_bb0025) 2023; 13
Sekine (10.1016/j.vaccine.2025.127420_bb0060) 2020; 183
Peng (10.1016/j.vaccine.2025.127420_bb0045) 2022; 23
Cele (10.1016/j.vaccine.2025.127420_bb0075) 2022; 602
References_xml – volume: 602
  start-page: 654
  year: 2022
  end-page: 656
  ident: bb0075
  article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
  publication-title: Nature
– volume: 6
  start-page: eabl5344
  year: 2021
  ident: bb0095
  article-title: BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype
  publication-title: Sci Immunol
– year: 2022
  ident: bb0225
  publication-title: Moderna
– year: 2022
  ident: bb0230
  publication-title: Pfizer-BioNTech
– volume: 9
  start-page: 99
  year: 2024
  ident: bb0190
  article-title: Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines
  publication-title: NPJ Vaccines
– volume: 73
  start-page: 330
  year: 2024
  end-page: 338
  ident: bb0200
  article-title: Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021-2023
  publication-title: MMWR Morb Mortal Wkly Rep
– volume: 21
  start-page: 1336
  year: 2020
  end-page: 1345
  ident: bb0050
  article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
  publication-title: Nat Immunol
– volume: 385
  year: 2021
  ident: bb0140
  article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months
  publication-title: N Engl J Med
– volume: 27
  start-page: 1280
  year: 2021
  end-page: 1289
  ident: bb0070
  article-title: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer
  publication-title: Nat Med
– volume: 375
  start-page: 43
  year: 2022
  end-page: 50
  ident: bb0005
  article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
  publication-title: Science
– volume: 23
  start-page: 50
  year: 2022
  end-page: 61
  ident: bb0045
  article-title: An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
  publication-title: Nat Immunol
– volume: 1
  year: 2020
  ident: bb0065
  article-title: Robust T cell response toward spike, membrane, and Nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients
  publication-title: Cell Rep Med
– volume: 54
  start-page: 2133
  year: 2021
  end-page: 2142
  ident: bb0150
  article-title: Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
  publication-title: Immunity
– volume: 28
  start-page: 1932
  year: 2010
  end-page: 1941
  ident: bb0170
  article-title: Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive
  publication-title: Vaccine
– volume: 185
  start-page: 2434
  year: 2022
  end-page: 2451
  ident: bb0130
  article-title: Humoral and cellular immune memory to four COVID-19 vaccines
  publication-title: Cell
– volume: 8
  start-page: 737
  year: 2008
  end-page: 744
  ident: bb0180
  article-title: The X-files in immunity: sex-based differences predispose immune responses
  publication-title: Nat Rev Immunol
– volume: 10
  year: 2021
  ident: bb0155
  article-title: mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
  publication-title: Elife
– volume: 377
  start-page: 821
  year: 2022
  end-page: 822
  ident: bb0085
  article-title: T cell immunity to COVID-19 vaccines
  publication-title: Science
– volume: 75
  start-page: S61
  year: 2022
  end-page: S71
  ident: bb0205
  article-title: Association of Frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced immunity in older adults
  publication-title: Clin Infect Dis
– volume: 15
  start-page: 1104
  year: 2014
  end-page: 1115
  ident: bb0035
  article-title: Molecular regulation of effector and memory T cell differentiation
  publication-title: Nat Immunol
– volume: 373
  start-page: 1372
  year: 2021
  end-page: 1377
  ident: bb0145
  article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
  publication-title: Science
– volume: 374
  start-page: eabj9853
  year: 2021
  ident: bb0100
  article-title: Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
  publication-title: Science
– volume: 8
  start-page: 134
  year: 2023
  ident: bb0135
  article-title: Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN((R)) induced immunity in COVID-19 exposed Indians
  publication-title: NPJ Vaccines
– volume: 385
  start-page: 951
  year: 2021
  end-page: 953
  ident: bb0120
  article-title: Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination
  publication-title: N Engl J Med
– volume: 603
  start-page: 493
  year: 2022
  end-page: 496
  ident: bb0125
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron
  publication-title: Nature
– volume: 13
  start-page: 6505
  year: 2023
  ident: bb0025
  article-title: Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
  publication-title: Sci Rep
– volume: 603
  start-page: 488
  year: 2022
  end-page: 492
  ident: bb0030
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize omicron
  publication-title: Nature
– volume: 386
  start-page: 2243
  year: 2022
  end-page: 2245
  ident: bb0080
  article-title: Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa
  publication-title: N Engl J Med
– volume: 597
  start-page: 268
  year: 2021
  end-page: 273
  ident: bb0115
  article-title: Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine
  publication-title: Nature
– volume: 13
  start-page: 2498
  year: 2003
  end-page: 2504
  ident: bb0235
  article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks
  publication-title: Genome Res
– volume: 2
  year: 2021
  ident: bb0040
  article-title: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
  publication-title: Cell Rep Med
– volume: 2
  year: 2021
  ident: bb0165
  article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals
  publication-title: Cell Rep Med
– volume: 369
  year: 2020
  ident: bb0160
  article-title: Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
  publication-title: Science
– volume: 185
  start-page: 847
  year: 2022
  end-page: 859
  ident: bb0105
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron
  publication-title: Cell
– volume: 183
  start-page: 996
  year: 2020
  end-page: 1012 e1019
  ident: bb0055
  article-title: Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
  publication-title: Cell
– year: 2020
  ident: bb0220
  article-title: J. F. Inside the new mRNA vaccines for COVID-19
– volume: 183
  start-page: 158
  year: 2020
  end-page: 168 e114
  ident: bb0060
  article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
  publication-title: Cell
– volume: 6
  year: 2018
  ident: bb0210
  article-title: Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials
  publication-title: Vaccines (Basel)
– volume: 588
  start-page: 315
  year: 2020
  end-page: 320
  ident: bb0185
  article-title: Sex differences in immune responses that underlie COVID-19 disease outcomes
  publication-title: Nature
– volume: 374
  start-page: abm0829
  year: 2021
  ident: bb0110
  article-title: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
  publication-title: Science
– volume: 124
  start-page: 13
  year: 2008
  end-page: 22
  ident: bb0195
  article-title: Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
  publication-title: Immunology
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  ident: bb0020
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N Engl J Med
– volume: 20
  start-page: 442
  year: 2020
  end-page: 447
  ident: bb0175
  article-title: Considering how biological sex impacts immune responses and COVID-19 outcomes
  publication-title: Nat Rev Immunol
– volume: 590
  start-page: 630
  year: 2021
  end-page: 634
  ident: bb0090
  article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
– volume: 385
  year: 2021
  ident: bb0015
  article-title: Waning immunity after the BNT162b2 vaccine in Israel
  publication-title: N Engl J Med
– volume: 27
  start-page: 1205
  year: 2021
  end-page: 1211
  ident: bb0010
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
– volume: 3
  start-page: 82
  year: 2023
  end-page: 92
  ident: bb0215
  article-title: Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination
  publication-title: Nat Aging
– volume: 6
  start-page: eabl5344
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0095
  article-title: BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abl5344
– volume: 603
  start-page: 488
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0030
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
– volume: 2
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0165
  article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals
  publication-title: Cell Rep Med
– volume: 383
  start-page: 2603
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0020
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
– volume: 185
  start-page: 847
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0105
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.015
– volume: 9
  start-page: 99
  year: 2024
  ident: 10.1016/j.vaccine.2025.127420_bb0190
  article-title: Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-024-00895-z
– volume: 13
  start-page: 2498
  year: 2003
  ident: 10.1016/j.vaccine.2025.127420_bb0235
  article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks
  publication-title: Genome Res
  doi: 10.1101/gr.1239303
– volume: 27
  start-page: 1205
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0010
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01377-8
– volume: 590
  start-page: 630
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0090
  article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
  doi: 10.1038/s41586-020-03041-6
– volume: 374
  start-page: abm0829
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0110
  article-title: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
  publication-title: Science
  doi: 10.1126/science.abm0829
– volume: 73
  start-page: 330
  year: 2024
  ident: 10.1016/j.vaccine.2025.127420_bb0200
  article-title: Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021-2023
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm7315a2
– year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0230
– volume: 377
  start-page: 821
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0085
  article-title: T cell immunity to COVID-19 vaccines
  publication-title: Science
  doi: 10.1126/science.add2897
– volume: 588
  start-page: 315
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0185
  article-title: Sex differences in immune responses that underlie COVID-19 disease outcomes
  publication-title: Nature
  doi: 10.1038/s41586-020-2700-3
– volume: 597
  start-page: 268
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0115
  article-title: Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine
  publication-title: Nature
  doi: 10.1038/s41586-021-03841-4
– volume: 183
  start-page: 158
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0060
  article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.017
– volume: 185
  start-page: 2434
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0130
  article-title: Humoral and cellular immune memory to four COVID-19 vaccines
  publication-title: Cell
  doi: 10.1016/j.cell.2022.05.022
– volume: 8
  start-page: 134
  year: 2023
  ident: 10.1016/j.vaccine.2025.127420_bb0135
  article-title: Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN((R)) induced immunity in COVID-19 exposed Indians
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-023-00731-w
– volume: 54
  start-page: 2133
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0150
  article-title: Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.08.001
– volume: 15
  start-page: 1104
  year: 2014
  ident: 10.1016/j.vaccine.2025.127420_bb0035
  article-title: Molecular regulation of effector and memory T cell differentiation
  publication-title: Nat Immunol
  doi: 10.1038/ni.3031
– volume: 23
  start-page: 50
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0045
  article-title: An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease
  publication-title: Nat Immunol
  doi: 10.1038/s41590-021-01084-z
– volume: 75
  start-page: S61
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0205
  article-title: Association of Frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced immunity in older adults
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciac397
– volume: 10
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0155
  article-title: mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status
  publication-title: Elife
  doi: 10.7554/eLife.72619
– volume: 28
  start-page: 1932
  year: 2010
  ident: 10.1016/j.vaccine.2025.127420_bb0170
  article-title: Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.10.091
– volume: 20
  start-page: 442
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0175
  article-title: Considering how biological sex impacts immune responses and COVID-19 outcomes
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-0348-8
– volume: 385
  start-page: 951
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0120
  article-title: Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2108829
– volume: 183
  start-page: 996
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0055
  article-title: Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.038
– volume: 385
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0015
  article-title: Waning immunity after the BNT162b2 vaccine in Israel
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2114228
– volume: 124
  start-page: 13
  year: 2008
  ident: 10.1016/j.vaccine.2025.127420_bb0195
  article-title: Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2008.02813.x
– volume: 1
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0065
  article-title: Robust T cell response toward spike, membrane, and Nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients
  publication-title: Cell Rep Med
– volume: 369
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0160
  article-title: Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
  publication-title: Science
  doi: 10.1126/science.abc8511
– volume: 6
  year: 2018
  ident: 10.1016/j.vaccine.2025.127420_bb0210
  article-title: Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials
  publication-title: Vaccines (Basel)
– volume: 374
  start-page: eabj9853
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0100
  article-title: Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells
  publication-title: Science
  doi: 10.1126/science.abj9853
– volume: 373
  start-page: 1372
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0145
  article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
  publication-title: Science
  doi: 10.1126/science.abj4176
– volume: 386
  start-page: 2243
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0080
  article-title: Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2202061
– volume: 21
  start-page: 1336
  year: 2020
  ident: 10.1016/j.vaccine.2025.127420_bb0050
  article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
  publication-title: Nat Immunol
  doi: 10.1038/s41590-020-0782-6
– year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0225
– volume: 27
  start-page: 1280
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0070
  article-title: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01386-7
– volume: 13
  start-page: 6505
  year: 2023
  ident: 10.1016/j.vaccine.2025.127420_bb0025
  article-title: Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study
  publication-title: Sci Rep
  doi: 10.1038/s41598-023-33320-x
– volume: 603
  start-page: 493
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0125
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04465-y
– volume: 3
  start-page: 82
  year: 2023
  ident: 10.1016/j.vaccine.2025.127420_bb0215
  article-title: Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination
  publication-title: Nat Aging
  doi: 10.1038/s43587-022-00343-4
– volume: 8
  start-page: 737
  year: 2008
  ident: 10.1016/j.vaccine.2025.127420_bb0180
  article-title: The X-files in immunity: sex-based differences predispose immune responses
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2394
– volume: 375
  start-page: 43
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0005
  article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
  publication-title: Science
  doi: 10.1126/science.abm3425
– volume: 385
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0140
  article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2114583
– volume: 2
  year: 2021
  ident: 10.1016/j.vaccine.2025.127420_bb0040
  article-title: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
  publication-title: Cell Rep Med
– volume: 602
  start-page: 654
  year: 2022
  ident: 10.1016/j.vaccine.2025.127420_bb0075
  article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
  publication-title: Nature
  doi: 10.1038/s41586-021-04387-1
SSID ssj0005319
Score 2.47828
Snippet Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate...
AbstractSevere SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 127420
SubjectTerms Adult
Allergy and Immunology
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
CD4 antigen
CD4-Positive T-Lymphocytes - immunology
CD8 antigen
CD8-Positive T-Lymphocytes - immunology
Cells
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 vaccine
COVID-19 vaccines
COVID-19 Vaccines - immunology
Cytokines
Cytokines - immunology
Cytokines - metabolism
FDA approval
Female
Humans
Immune response
Immune response (cell-mediated)
Immune system
Immunity (Disease)
Immunity, Cellular
Immunological memory
Immunoregulation
Infections
Lymphocytes T
Male
Middle Aged
mRNA
mRNA vaccines
Proteins
Questionnaires
SARS-CoV-2
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Sex differences
Sex Factors
Sociodemographics
Spike Glycoprotein, Coronavirus - immunology
Stains & staining
T-cell
Vaccination
Vaccines
Vectors (Biology)
Viral diseases
Viral infections
Young Adult
Title COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X25007170
https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X25007170
https://dx.doi.org/10.1016/j.vaccine.2025.127420
https://www.ncbi.nlm.nih.gov/pubmed/40561567
https://www.proquest.com/docview/3242375100
https://www.proquest.com/docview/3224254745
Volume 61
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQyBeEJSvjjEZCe1pbpPYcZrHqjB1oJVp7aq-WXbiSJ0gnZp22l74W_hb-Mu4y0cLggnEYxKfEufOd_ez7wPgrU8lyxNheYqIlsssjrmxWcpDkTj0HpwSZSml05EaXsgPs3C2A4MmF4bCKmvdX-n0UlvXd7r13-xezefdsVfacm-GRpxACeF2KSOS9c7Xn8I8RNncgwZzGr3N4uledq5NQsfXCBODsOPTqaV3l326y_8s7dDxY3hUO5CsX33jE9hxeQvuVy0lb1vw4LQ-LG_B4VlVlvr2iE22WVbFETtkZ9uC1UjTmlJMTJmYyxryp5AOPk1P3nE_Zl_OR322WDKKB_7Mrst9flZPitEeLjN5yoq1pT0dVrgbNm9anzD0L9m4fz7mg8WUB9-_TTgdFbBlFZrrnsHF8fvJYMjrngw8QWy04soo4WSWGrStBvW8yyz6bC7OEGklNlZhoJDf0o-iJA49Ra3MnRNZJkSmVGh64jns5ovcvQQWCfSFMt_61rPSBAjdYpeY2PVStKbOyTZ0Gk7oq6r0hm5i0i51PUtNrNMV69qgGn7pJq8UNaFG4_A3wuhPhK6o13OhfV0E2tO_yVwbehvKX8T2X16634iU3ryndG8j1JP4-M3mMa544o3J3WJNYwgmykiGbXhRieLm_0gChKGK9v7_u17BQ7qifXNf7MPuarl2r9HxWtmDcmUdwL3-ycfh6AdskSrH
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQ3y8oFFgFDYwEtrT3Cax4zSPVcfUwVqmtav6ZjmJI3WCdGraib3wt_C38JftLh8tCCYQr7FPSXznu_vZ9wHwzqWS5bGIeIKIlss0DLmJ0oT7IrboPVglilJKg6HqX8gPU3-6Bb06F4bCKivdX-r0QltXT9rVaravZrP2yClsuTNFI06gBHH7PUltDlCoW99-ivMQRXcPms1p-iaNp33ZujYx3V8jTvT8lkvXls5dBuouB7QwRMc78LjyIFm3_MgnsGWzBtwve0reNODBoLotb8DBWVmX-uaQjTdpVvkhO2Bnm4rVSNOYUFBMkZnLavKnkPQ-TU6OuBuyL-fDLpsvGAUEf2bXxUE_q36K0SEuM1nC8lVEhzost1_ZrO59wtDBZKPu-Yj35hPu_fg-5nRXwBZlbK59BhfH78e9Pq-aMvAYwdGSK6OElWli0LgaVPQ2jdBps2GKUCuOQuV7Chku3SCIQ99R1MvcWpGmQqRK-aYjnsN2Ns_sC2CBQGcodSM3ciJpPMRuoY1NaDsJmlNrZRNaNSf0VVl7Q9dBaZe6-ktNrNMl65qgan7pOrEUVaFG6_A3wuBPhDavNnSuXZ172tG_CV0TOmvKX-T2X166V4uUXr-n8G8DVJQ4_HY9jFueeGMyO1_RHMKJMpB-E3ZLUVyvjyRE6Kvg5f9_1xt42B8PTvXpyfDjK3hEI3SI7oo92F4uVnYfvbBl9LrYZbfq8yxQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+mRNA+or+viral+vector+vaccine+type+and+subject+sex+influence+the+SARS-CoV-2%C2%A0T-cell+response&rft.jtitle=Vaccine&rft.au=Tong%2C+Sherry&rft.au=Litwin%2C+Sean+M&rft.au=Epel%2C+Elissa+S&rft.au=Lin%2C+Jue&rft.date=2025-08-13&rft.issn=0264-410X&rft.volume=61&rft.spage=127420&rft.epage=127420&rft_id=info:doi/10.1016%2Fj.vaccine.2025.127420&rft.externalDBID=ECK1-s2.0-S0264410X25007170&rft.externalDocID=1_s2_0_S0264410X25007170
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X25X00165%2Fcov150h.gif